Regulus Therapeutics

Regulus Therapeutics is a company listed under the stock ticker RGLS (US).

View the org chart displaying its 23 main executives

Most searched biographies at Regulus Therapeutics

• Joseph Hagan, President, Chief Executive Officer and Director
• David Baltimore, Director
• Kathryn Collier, Director

Create your alert
to follow the executive moves at Regulus Therapeutics.

Regulus Therapeutics has 2,281 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
• Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
• Histogen has filed for bankruptcy protection  (posted on April 19 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion
• Vik Bajaj - Director at Interline Therapeutics

Learn more about the Biotechnology industry >

Press releases by Regulus Therapeutics

• Press Releases - Regulus Therapeutics
• Press Releases - Regulus Therapeutics
• Press Releases - Regulus Therapeutics
• Press Releases - Regulus Therapeutics
• Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference | Regulus Therapeutics Inc.
• Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates | Regulus Therapeutics Inc.
• Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Regulus Therapeutics Inc.
• Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call | Regulus Therapeutics Inc.
• Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital | Regulus Therapeutics Inc.
• Regulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Updates | Regulus Therapeutics Inc.
• View more press releases Close

Social media about Regulus Therapeutics

• Regulus Therapeutics on Wikipedia, Google News & Yahoo Finance
• Regulus Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Kathryn Collier

Call Regulus Therapeutics at +1 888...

View the org chart

Register to receive your alert

Report an error